구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | IL-15 Superagonist (N-803, N-803 (IL-15 Superagonist)) ImmunityBio, Inc.·High-risk Prostate Cancer 57 trials |
|---|---|
Overview Program | N-803 (IL-15 Superagonist) |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | High-risk Prostate Cancer |
Overview Indication | High-risk Prostate Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy using expanded natural killer cells |
MoA Mechanism | ADCC) and complement-dependent cytotoxicity (CDC) |
MoA Biomarker | biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances i |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Safety signal | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Selected reported efficacy | ORR 80% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02384954 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | IL-15 Superagonist (N-803, N-803 (IL-15 Superagonist)) ImmunityBio, Inc.·High-risk Prostate Cancer 57 trials |
|---|---|
Overview Program | N-803 (IL-15 Superagonist) |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | High-risk Prostate Cancer |
Overview Indication | High-risk Prostate Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy using expanded natural killer cells |
MoA Mechanism | ADCC) and complement-dependent cytotoxicity (CDC) |
MoA Biomarker | biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances i |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Safety signal | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Selected reported efficacy | ORR 80% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02384954 |
추천 비교
추천 비교